Sunzen Biotech Berhad (KLSE: SUNZEN)
Malaysia
· Delayed Price · Currency is MYR 0.315
-0.005 (-1.56%)
At close: Nov 14, 2024
Sunzen Biotech Berhad Income Statement
Financials in millions MYR. Fiscal year is July - June.
Millions MYR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 95.12 | 95.12 | 98.13 | 97.09 | 90.48 | 82.23 | Upgrade
|
| Revenue Growth (YoY) | 3.73% | -3.07% | 1.07% | 7.31% | 10.03% | -65.82% | Upgrade
|
| Cost of Revenue | 69.57 | 69.57 | 67.55 | 73.17 | 74.58 | 74.24 | Upgrade
|
| Gross Profit | 25.55 | 25.55 | 30.58 | 23.93 | 15.9 | 7.99 | Upgrade
|
| Selling, General & Admin | 13.02 | 13.02 | 18.36 | 14.74 | 12.81 | 20.03 | Upgrade
|
| Other Operating Expenses | 1.26 | 1.26 | - | 1.6 | 0.84 | 3.16 | Upgrade
|
| Operating Expenses | 14.46 | 14.46 | 18.36 | 16.11 | 11.97 | 20.18 | Upgrade
|
| Operating Income | 11.09 | 11.09 | 12.22 | 7.81 | 3.93 | -12.19 | Upgrade
|
| Interest Expense | -0.29 | -0.29 | -0.27 | -0.21 | -0.26 | -0.6 | Upgrade
|
| Interest & Investment Income | 0.04 | 0.04 | - | 0.04 | 0.04 | 0.09 | Upgrade
|
| Earnings From Equity Investments | -0.28 | -0.28 | -0.19 | -0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 10.57 | 10.57 | 11.77 | 7.64 | 3.72 | -12.7 | Upgrade
|
| Asset Writedown | - | - | - | -0.18 | -0.01 | - | Upgrade
|
| Pretax Income | 10.57 | 10.57 | 11.77 | 7.46 | 3.71 | -12.7 | Upgrade
|
| Income Tax Expense | 3.52 | 3.52 | 3.77 | 2.7 | 1.77 | 0.21 | Upgrade
|
| Earnings From Continuing Operations | 7.05 | 7.05 | 8 | 4.77 | 1.94 | -12.91 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -0.02 | - | - | - | Upgrade
|
| Net Income to Company | 7.05 | 7.05 | 7.98 | 4.77 | 1.94 | -12.91 | Upgrade
|
| Minority Interest in Earnings | -1.03 | -1.03 | -1.18 | -1.02 | -1.26 | -0.32 | Upgrade
|
| Net Income | 6.03 | 6.03 | 6.8 | 3.75 | 0.68 | -13.23 | Upgrade
|
| Net Income to Common | 6.03 | 6.03 | 6.8 | 3.75 | 0.68 | -13.23 | Upgrade
|
| Net Income Growth | 47.64% | -11.35% | 81.34% | 451.17% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 705 | 705 | 705 | 708 | 562 | 529 | Upgrade
|
| Shares Outstanding (Diluted) | 824 | 824 | 766 | 799 | 599 | 529 | Upgrade
|
| Shares Change (YoY) | 0.56% | 7.67% | -4.24% | 33.52% | 13.24% | 0.15% | Upgrade
|
| EPS (Basic) | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | -0.03 | Upgrade
|
| EPS (Diluted) | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | -0.03 | Upgrade
|
| EPS Growth | 45.21% | -17.61% | 89.40% | 327.18% | - | - | Upgrade
|
| Free Cash Flow | 9.2 | 9.2 | 8.86 | -34.34 | -18.76 | 6.04 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | 0.01 | 0.01 | -0.04 | -0.03 | 0.01 | Upgrade
|
| Gross Margin | 26.86% | 26.86% | 31.16% | 24.64% | 17.58% | 9.72% | Upgrade
|
| Operating Margin | 11.66% | 11.66% | 12.45% | 8.05% | 4.34% | -14.82% | Upgrade
|
| Profit Margin | 6.34% | 6.34% | 6.93% | 3.86% | 0.75% | -16.09% | Upgrade
|
| Free Cash Flow Margin | 9.67% | 9.67% | 9.03% | -35.37% | -20.73% | 7.35% | Upgrade
|
| EBITDA | 13.07 | 13.07 | 14.36 | 10.02 | 6.21 | -9.88 | Upgrade
|
| EBITDA Margin | 13.74% | 13.74% | 14.64% | 10.32% | 6.86% | -12.02% | Upgrade
|
| D&A For EBITDA | 1.97 | 1.97 | 2.14 | 2.2 | 2.28 | 2.3 | Upgrade
|
| EBIT | 11.09 | 11.09 | 12.22 | 7.81 | 3.93 | -12.19 | Upgrade
|
| EBIT Margin | 11.66% | 11.66% | 12.45% | 8.05% | 4.34% | -14.82% | Upgrade
|
| Effective Tax Rate | 33.27% | 33.27% | 32.01% | 36.12% | 47.70% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.